Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline...

Full description

Saved in:
Bibliographic Details
Published in:NPJ breast cancer 2023-08, Vol.9 (1), p.70-70, Article 70
Main Authors: Hanna, Paul E., Strohbehn, Ian A., Moreno, Daiana, Harden, Destiny, Seethapathy, Rituvanthikaa, Sawtell, Rani, Wang, Qiyu, Ouyang, Tianqi, Katz-Agranov, Nurit, Dinulos, James, Wander, Seth A., Gupta, Shruti, Sise, Meghan E.
Format: Article
Language:English
Subjects:
631/67/322
692/4028/67/1347
692/499
692/699/67/1347
Biomedical and Life Sciences
Biomedicine
Breast cancer
Brief Communication
Cancer Research
Cardiovascular disease
Cell Biology
Coronary vessels
Creatinine
Cyclin-dependent kinases
Diuretics
Hematuria
Human Genetics
Hypertension
Kidneys
Kinases
Medical research
Medicine
Metastasis
Oncology
Patients
Regression analysis
Renal replacement therapy
Standard deviation
Variance analysis
Vein & artery diseases
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.
ISSN:2374-4677
2374-4677
DOI:10.1038/s41523-023-00576-5